DesvenlafaxineEfficacy and Safety Study of Desvenlafaxine in the Treatment of Vascular Depression

Inclusion Criteria:

1. Evidence of a personally signed and dated informed consent document indicating that the subject (or a legally acceptable representative) has been informed of all pertinent aspects of the study.
2. Male or female subject between 60 and 80 years of age, at the time of consent.
3. Diagnosis of Major Depressive Disorder according to DSM-IV-TR at screening.
4. Evidence of DWMH on MRI
5. Cognitive deficits not meeting criteria for dementia (MMSE higher or equal 21, Clinical Dementia Rating CDR=0.5, not meeting criteria on DSM IV TR)
6. Subjects are willing and able to comply with scheduled visits, treatment plan, and other study procedures

Exclusion Criteria:

1. Subjects who have a history of repeated non-compliance with treatment.
2. Subjects with any contraindication(s) to desvenlafaxine, in accordance with product monograph
3. Subjects with known or suspected narrow angle glaucoma
4. Subjects currently being treated with anticoagulants
5. Subjects with known hypertension or uncontrolled diabetes
6. Subjects who meet criteria for an active DSM-IV-TR Axis I diagnosis other than Major Depressive Disorder (Cognitive Disorder NOS is permitted but not dementia)
7. Subjects prescribed any Selective Serotonin Reuptake Inhibitors (SSRIs), Serotonin-Norepinephrine Reuptake inhibitors (SNRIs), or typical or atypical antipsychotic medications other than the medications being studied
8. Subjects with a diagnosis of a psychotic disorder or currently experiencing psychotic symptoms
9. Subjects judged by the investigator as being at significant risk of self-injurious/suicidal or violent/homicidal behavior
10. Subjects who have experienced symptoms of a CVA
11. Subjects with TIAs within the past 6 weeks